GLP-1 Drug Surge Drives 5-10% Drop in UK Potato Demand, Pushing Growers to Cut Crisp Orders

Potato demand in the UK has declined 5–10% year-over-year as GLP-1 weight-loss injections, now used by about 2.5 million people, drive reduced consumption of salty and starchy foods. Sales of fresh potatoes fell 2.1% in volume, with frozen chips and crisping potatoes hit hardest, as consumers shift toward “side of plate” and “nutrient-dense” options perceived as healthier. Supermarkets and restaurants are adapting menus to cater to the trend, including Marks & Spencer’s nutrient-dense range and Morrisons’ GLP-1-friendly ready meals. Worldpanel data shows consumers on weight-loss drugs eating 46% less salty snacks, 49% less sweet snacks, 71% less beer, wine and spirits, and 45% less tobacco. RS Cockerill and other growers report 5–7% overall weaker demand and as much as 10% less crisp potato required. The sector also faces a bumper harvest-driven glut, with Maris Piper potatoes selling at about £180 per tonne—half their 2024 price—amid a broader health-conscious shift and smaller portion sizes in fish and chip shops.